Table: q1_q4_2022_prescription_drug_wac_increases , manufacturer_name like F*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id manufacturer_name date_reported ndc_number drug_product_description wac_effective_date wac_increase_amount wac_after_increase patent_expiration_date drug_source_type unit_sales_volume_in_us unit_sales_volume_non_public_indicator cost_increase_factors cost_increase_factors_non_public_indicator change_improvement_description change_improvement_non_public_indicator acquisition_date company_acquired_from acquisition_price acquisition_price_non_public_indicator acquisition_price_comment wac_at_acquisition wac_year_prior_to_acquisition year_drug_introduced_to_market wac_at_intro_to_market supporting_documents general_comments
Rx0000063 Ferring Pharmaceuticals 06/30/2022 55566280001 CERVIDIL 10MG VAGINAL INSERT (Dinoprostone 10MG) 04/01/2022 22.85 479.84 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The acquisition fields do not apply because Ferring did not acquire the product within the past five years.
Rx0000063 Ferring Pharmaceuticals 06/30/2022 55566750102 Menopur (Menotropins for injection)/75 nits/vial - 5 single dose vials per package 06/01/2022 32.70 1122.15 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The acquisition fields do not apply because Ferring did not acquire the product within the past five years. NDC 55566750101 is the NDC for the 0.9% Sodium Chloride Injection, USP, 2 mL product included in the Menopur kit. The Sodium Chloride is used for mixing the medicine. NDC 55566750101 does not have a WAC price
Rx0000193 Forte Bio-Pharma, LLC 03/31/2022 72245019310 NALOCET 2.5MG/300MG 100CT TABLETS 01/01/2022 132.19 2776.04 None Non-innovator Multiple Source Drug 4200 None Forte Bio considers many factors in the pricing of our products including but not limited to constant competition in the marketplace requires frequent reassements of pricing to ensure consistency with current market, market share has a determining factor on our pricing as we determine our pricing structure to ensure our place in the market, patient population contributes to each pricing decision as this helps determine the profitability of the product and the cost to market our products is continuously rising as we need more resources to properly market the products. None None 1 None None None None None None None None None None None
Rx0000129 Fresenius Kabi USA LLC 12/31/2022 63323061603 Amiodarone HCl Intravenous Solution 150 MG/3ML Package Size 25 12/09/2022 5.25 43.75 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000129 Fresenius Kabi USA LLC 03/31/2022 63323051610 Dexamethasone Sodium Phosphate Inj 100mg 10mL MDV 10 10ML Vials 01/07/2022 12.30 141.50 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000129 Fresenius Kabi USA LLC 03/31/2022 63323050601 Dexamethasone Sodium Phosphate Inj 10mg 1mL PF SDV 1 25ML Vial 01/07/2022 14.75 171.25 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000129 Fresenius Kabi USA LLC 12/31/2022 63323016530 Dexamethasone Sodium Phosphate Injection Solution 120 MG/30ML Package Size 1 12/09/2022 3.53 40.71 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000129 Fresenius Kabi USA LLC 12/31/2022 76045010610 Dexamethasone Sodium Phosphate Injection Solution 4 MG/ML Package Size 24 11/23/2022 31.86 69.36 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000129 Fresenius Kabi USA LLC 03/31/2022 63323017302 Gentamicin Inj 20mg 2mL PF MDV 2 25ML Vials 01/07/2022 10.25 117.50 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000129 Fresenius Kabi USA LLC 09/30/2022 63323017394 Gentamicin Sulfate Injection Solution 10 MG/ML 07/01/2022 3.75 49.50 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000129 Fresenius Kabi USA LLC 12/31/2022 63323085110 HYDROmorphone HCl PF Injection Solution 10 MG/ML Package Size 10 12/09/2022 7.80 47.00 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000129 Fresenius Kabi USA LLC 12/31/2022 76045000120 Midazolam HCl (PF) Injection Solution 2 MG/2ML Package Size 24 11/23/2022 18.00 66.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000129 Fresenius Kabi USA LLC 03/31/2022 63323001230 Oxytocin Inj 300USP 30mL MDV 1 Vial 01/07/2022 37.50 432.50 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000129 Fresenius Kabi USA LLC 12/31/2022 63323018620 Sodium Chloride (PF) Injection Solution 0.9 % Package Size 25 12/09/2022 6.00 45.75 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000129 Fresenius Kabi USA LLC 03/31/2022 49230064551 Velphoro 90 Count Per Bottle of 500 MG Oral Tablets Chewable 01/07/2022 57.74 1501.25 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000129 Fresenius Kabi USA LLC 03/31/2022 63323048257 Xylocaine (Lidocaine HCl) Inj w EPI 500mg 50mL MDV 25pk Single Vial 01/07/2022 20.50 236.25 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000100 Fresenius Medical Care 09/30/2022 49230064551 VELPHORO 500MG CHEWABLE TABLETS 90 TABLET BOTTLE 09/01/2022 30.03 1531.28 05/26/2035 Single Source Drug None 1 The increase in Wholesale Acquisition Cost (WAC) for the products is due to increases in the costs of manufacturing and distribution, specifically including increases in the cost of the active pharmaceutical ingredients (API) of the products, increases in shipping for the products, and increases in costs to market the products. None This WAC increase is not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None Please note that this report and its contents are exempted from disclosure under the California Public Records Act, Cal. Gov. Code ? 6250 et seq. (?PRA?) as the material contains and constitutes FUSA?s proprietary commercial information and otherwise would not be in the public interest to disclose. Please contact Domenic Gaeta at domenic.gaeta@fmc-na.com regarding any PRA requests so that we may take appropriate steps to protect such information. Fresenius Medical Care is the authorized distributor for Velphoro. Fresenius Medical Care did not acquire Velphoro in the prior five year period.